Scienture Holdings, Inc. (NASDAQ:SCNX) Short Interest Down 48.4% in July

Scienture Holdings, Inc. (NASDAQ:SCNX) was the recipient of a significant drop in short interest in July. As of July 31st, there was short interest totaling 1,341,608 shares, a drop of 48.4% from the July 15th total of 2,600,386 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 317,449 shares, the days-to-cover ratio is presently 4.2 days.

Institutional Trading of Scienture

A hedge fund recently raised its stake in Scienture stock. Geode Capital Management LLC raised its position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 316,201 shares of the company’s stock after purchasing an additional 229,398 shares during the quarter. Geode Capital Management LLC owned 0.78% of Scienture worth $161,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.68% of the company’s stock.

Scienture Stock Up 0.2%

SCNX stock opened at $0.47 on Friday. The business has a 50 day moving average of $0.38 and a 200 day moving average of $0.40. The firm has a market cap of $18.93 million, a PE ratio of -0.22 and a beta of 3.26. Scienture has a twelve month low of $0.24 and a twelve month high of $2.60.

Scienture (NASDAQ:SCNX) last released its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.96 million.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $1.50.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.